Clinical Trials Logo

Clinical Trial Summary

DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with biopsy-proven FSGS who are being treated with an ARB.


Clinical Trial Description

This is a pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS. The total study duration per patient is estimated to be maximum of 122 weeks, including a 4-week Screening period, a Titration period (if required, for not more than 4 weeks), a 6-week Stabilization period, a 104-week Treatment period, and up to a 4-week off-treatment Follow-up period. This is a hybrid virtual study which will utilize a decentralized model, ie, using a combination of on-site visits and optional remote visits ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05183646
Study type Interventional
Source Dimerix Bioscience Pty Ltd
Contact Alisha Smith
Phone 1300 813 321
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date February 2022
Completion date June 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04009668 - Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease Phase 2
Terminated NCT01451489 - The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis N/A
Completed NCT03536754 - A Study of CCX140-B in Subjects With FSGS Phase 2
Withdrawn NCT02399462 - Acthar for Treatment of Post-transplant FSGS Phase 4
Enrolling by invitation NCT04571658 - NEPTUNE Match Study
Recruiting NCT01468493 - A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients N/A
Terminated NCT01164098 - Rituximab to Prevent Recurrence of Proteinuria Phase 3
Recruiting NCT02683889 - Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation Phase 3